Cargando…

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease

OBJECTIVE: Improved risk assessment for patients with type 2 diabetes and elevated cardiovascular (CV) risk is needed. The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS 2°P) predicts a gradient of risk in patients with prior myocardial infarction (MI) but has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergmark, Brian A., Bhatt, Deepak L., Braunwald, Eugene, Morrow, David A., Steg, Ph. Gabriel, Gurmu, Yared, Cahn, Avivit, Mosenzon, Ofri, Raz, Itamar, Bohula, Erin, Scirica, Benjamin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2018
Materias:	Cardiovascular and Metabolic Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829964/ https://www.ncbi.nlm.nih.gov/pubmed/29196298 http://dx.doi.org/10.2337/dc17-1736

Ejemplares similares

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
por: Berg, David D., et al.
Publicado: (2021)

Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2022)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
por: McEwan, Phil, et al.
Publicado: (2021)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50
por: Berg, David D., et al.
Publicado: (2021)

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
por: Moura, Filipe A., et al.
Publicado: (2023)

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
por: Kidd, Stephen K., et al.
Publicado: (2016)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Early Insulinization to Prevent Diabetes Progression
por: Raz, Itamar, et al.
Publicado: (2013)

Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
por: Aoki, Yasunori, et al.
Publicado: (2021)

Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial
por: Gencer, Baris, et al.
Publicado: (2020)

Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2023)

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial
por: Furtado, Remo H. M., et al.
Publicado: (2020)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study
por: Kats, Dmitry, et al.
Publicado: (2017)

Risk Prediction of Cardiovascular Disease in Type 2 Diabetes: A risk equation from the Swedish National Diabetes Register
por: Cederholm, Jan, et al.
Publicado: (2008)

Dysglycemia and a History of Reproductive Risk Factors
por: McDonald, Sarah D., et al.
Publicado: (2008)

Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study
por: Fujita, Yuko, et al.
Publicado: (2022)

Glucose Intolerance in Pregnancy and Future Risk of Pre-Diabetes or Diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2008)

Levels of ankle–brachial index and the risk of diabetes mellitus complications
por: Alves-Cabratosa, Lia, et al.
Publicado: (2020)

Sedentary Time and Metabolic Risk in Extremely Active Older Adults
por: Madden, Kenneth M., et al.
Publicado: (2021)

ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk
por: Zhang, Hongmei, et al.
Publicado: (2020)

In Utero Exposure to Maternal Hyperglycemia Increases Childhood Cardiometabolic Risk in Offspring
por: Tam, Wing Hung, et al.
Publicado: (2017)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
por: Basu, Sanjay, et al.
Publicado: (2018)

Normal Glucose Values Are Associated With a Lower Risk of Mortality in Hospitalized Patients
por: Bruno, Alberto, et al.
Publicado: (2008)

Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S.
por: Hoang, Khiet C., et al.
Publicado: (2008)

Increased Risk of Cardiovascular Disease in Young Women Following Gestational Diabetes Mellitus
por: Shah, Baiju R., et al.
Publicado: (2008)

Genetic Risk Score Associations With Cardiovascular Disease and Mortality in the Diabetes Heart Study
por: Cox, Amanda J., et al.
Publicado: (2014)

Prevalence of diabetes and cardiovascular risk factors in middle-class urban participants in India
por: Gupta, Arvind, et al.
Publicado: (2014)

Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
por: Crandall, Jill P, et al.
Publicado: (2017)

Changes in Triglyceride Levels Over Time and Risk of Type 2 Diabetes in Young Men
por: Tirosh, Amir, et al.
Publicado: (2008)

Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program
por: Perreault, Leigh, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qpb4unrnuq0f09r3p6ojf2ono8